ClinicalTrials.gg
CompletedNCT01189487Updated Jul 13, 2012Results posted

The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)

A Phase 3 interventional study of ampicillin sodium/sulbactam sodium in Pneumonia, Bacterial, sponsored by Pfizer. Completed at 22 sites in Japan. Open to participants aged 16 Years to 79 Years. Per ClinicalTrials.gov, last updated 2012-07-13.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
16 Years to 79 Years
Sex
All
01

Study summary

Unasyn-S 12g/day (3 g four times a day) is the commonly used dosage depending on the severity for US, EU, China, Taiwan and Korea for over 20 years, however, Unasyn-S 12g/day has not yet been approved in Japan. The purpose of this trial is to evaluate the clinical efficacy and safety in Japanese adult subjects with community acquired pneumonia receiving ampicillin sodium/sulbactam sodium, 12g/day (3 g four times a day ) IV.

02

Conditions studied

  • Pneumonia, Bacterial

Keywords

  • ampicillin sodium/sulbactam sodium
  • Unasyn-S
  • community acquired pneumonia
  • bacterial pneumonia
03

In context

Pneumonia, Bacterial

153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.

This study's enrollment of 47 is below the median of 132 across 107 interventional studies indexed under Pneumonia, Bacterial.

Browse Pneumonia, Bacterial studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 16 years of age or older.
  • Patients who were diagnosed as moderate to severe community acquired pneumonia requiring initial intravenous therapy and hospitalization.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected or intolerance to ampicillin sodium/sulbactam sodium, other penicillins, or cephems.
  • Hepatic dysfunction [(AST), Alanine Aminotransferase (ALT), total > 3 times values].
  • Severe renal dysfunction ( \< 30 ml/min).
  • Severe underlying disease; patients in which drug clinical evaluation is difficult because of confounding diseases.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    ampicillin sodium/sulbactam sodium

    ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV

    Drug: ampicillin sodium/sulbactam sodium

Interventions

  • Drugampicillin sodium/sulbactam sodium

    Drug pages: Ampicillin · Sulbactam

    ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days

    Also known as: Unasyn-S

06

What researchers measure

Primary outcomes

  1. Response Rate (Clinical Response, Data Review Committee Assessment)

    Response rate was calculated from the following formula, "the number of participants assessed as effective" over "total participants excluding ones assessed as indeterminate" multiplied by 100.

    Time frame: End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)

Secondary outcomes

  1. Response Rate (Clinical Response, Investigator Assessment)

    Response rate was calculated from the following formula, "the number of participants assessed as effective" over "total participants EXCLUDING ones assessed as indeterminate" multiplied by 100.

    Time frame: End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)

  2. The Tendency Toward Clinical Improvement (Investigator Assessment)

    The number of participants who showed tendency toward clinical improvement based on the assessment of temperature, white blood cell count, C-reactive protein, clinical symptoms on Day 4 and was determined to continue the treatment.

    Time frame: Day 4

  3. Eradication Rate (Bacteriological Response, Data Review Committee Assessment)

    Eradication Rate was calculated from the following formula, "the number of participants assessed as eradication, presumed eradication or microbial substitution" over "total participants excluding ones assessed as indeterminate" multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment.

    Time frame: Day 4, End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)

  4. Eradication Rate (Bacteriological Response, Investigator Assessment)

    Eradication Rate was calculated from the following formula, "the number of participants assessed as eradication , presumed eradication or microbial substitution" over "total participants excluding ones assessed as indeterminate" multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment.

    Time frame: Day 4, End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)

07

Results

Posted May 18, 2012

Participant flow

Participant flow — Overall Study
MilestoneAmpicillin Sodium/Sulbactam Sodium
Started47
Completed44
Not completed3
Withdrew: Lack of efficacy2
Withdrew: Adverse event1

Outcome measures

PrimaryResponse Rate (Clinical Response, Data Review Committee Assessment)

Response rate was calculated from the following formula, "the number of participants assessed as effective" over "total participants excluding ones assessed as indeterminate" multiplied by 100.

Time frame:
End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)
Reported as:
Number · percentage of participants
Response Rate (Clinical Response, Data Review Committee Assessment)
percentage of participantsAmpicillin Sodium/Sulbactam Sodium
End of treatment (n=39)97.4 (86.5 to 99.9)
Test of cure (n=37)94.6 (81.8 to 99.3)
Long term follow up (n=36)94.4 (81.3 to 99.3)
SecondaryResponse Rate (Clinical Response, Investigator Assessment)

Response rate was calculated from the following formula, "the number of participants assessed as effective" over "total participants EXCLUDING ones assessed as indeterminate" multiplied by 100.

Time frame:
End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)
Reported as:
Number · percentage of participants
Response Rate (Clinical Response, Investigator Assessment)
percentage of participantsAmpicillin Sodium/Sulbactam Sodium
End of treatment (n=40)100.0 (91.2 to 100.0)
Test of cure (n=38)100.0 (90.7 to 100.0)
Long term follow up (n=34)100.0 (89.7 to 100.0)
SecondaryThe Tendency Toward Clinical Improvement (Investigator Assessment)

The number of participants who showed tendency toward clinical improvement based on the assessment of temperature, white blood cell count, C-reactive protein, clinical symptoms on Day 4 and was determined to continue the treatment.

Time frame:
Day 4
Reported as:
Number · percentage of participants
The Tendency Toward Clinical Improvement (Investigator Assessment)
percentage of participantsAmpicillin Sodium/Sulbactam Sodium
The Tendency Toward Clinical Improvement (Investigator Assessment)100.0
SecondaryEradication Rate (Bacteriological Response, Data Review Committee Assessment)

Eradication Rate was calculated from the following formula, "the number of participants assessed as eradication, presumed eradication or microbial substitution" over "total participants excluding ones assessed as indeterminate" multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment.

Time frame:
Day 4, End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)
Reported as:
Number · percentage of participants
Eradication Rate (Bacteriological Response, Data Review Committee Assessment)
percentage of participantsAmpicillin Sodium/Sulbactam Sodium
Day 4 (n=24)100.0 (85.8 to 100.0)
End of treatment (n=25)96.0 (79.6 to 99.9)
Test of cure (n=24)91.7 (73.0 to 99.0)
Long term follow up (n=21)95.2 (76.2 to 99.9)
SecondaryEradication Rate (Bacteriological Response, Investigator Assessment)

Eradication Rate was calculated from the following formula, "the number of participants assessed as eradication , presumed eradication or microbial substitution" over "total participants excluding ones assessed as indeterminate" multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment.

Time frame:
Day 4, End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)
Reported as:
Number · percentageof participants
Eradication Rate (Bacteriological Response, Investigator Assessment)
percentageof participantsAmpicillin Sodium/Sulbactam Sodium
Day 4 (n=23)95.7 (78.1 to 99.9)
End of treatment (n=24)100.0 (85.8 to 100.0)
Test of cure (n=23)95.7 (78.1 to 99.9)
Long term follow up (n=19)100.0 (82.4 to 100.0)

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ampicillin Sodium/Sulbactam Sodium—1/47 (2.1%)19/47 (40.4%)
Most frequent serious events
Most frequent serious events
EventAmpicillin Sodium/Sulbactam Sodium
PneumoniaInfections and infestations1/47
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAmpicillin Sodium/Sulbactam Sodium
Alanine aminotransferase increasedInvestigations7/47
Aspartate aminotransferase increasedInvestigations6/47
ConstipationGastrointestinal disorders5/47
Blood alkaline phosphatase increasedInvestigations4/47
DiarrhoeaGastrointestinal disorders3/47
NasopharyngitisInfections and infestations3/47
Gamma-glutamyltransferase increasedInvestigations3/47
PyrexiaGeneral disorders2/47
HeadacheNervous system disorders2/47
EczemaSkin and subcutaneous tissue disorders2/47

Baseline characteristics

Age Continuous
Age Continuous(years)Ampicillin Sodium/Sulbactam Sodium
Mean62.3 ± 16.4
Sex: Female, Male
Sex: Female, Male(Participants)Ampicillin Sodium/Sulbactam Sodium
Female21
Male26
08

Study locations

22 sites
  • Tosei General Hospital
    Seto-shi, Aichi-ken, Japan
  • National Hospital Organization Kokura Medical Center
    Kitakyushu, Fukuoka, Japan
  • University of Occupational and Environmental Health
    Kitakyushu, Fukuoka, Japan
  • Nagata Hospital
    Yanagawa, Fukuoka, Japan
  • National Hospital Organization Asahikawa Medical Center
    Asahikawa, Hokkaido, Japan
  • National Hokkaido Medical Center
    Sapporo, Hokkaido, Japan
  • National Hospital Organization Himeji Medical Center
    Himejishi, Hyogo, Japan
  • KKR Takamatsu Hospital
    Takamatsu, Kagawa, Japan
  • Nippon Koukan Hospital
    Kawasaki-city, Kanagawa, Japan
  • Kanagawa Cardiovascular and Respiratory Center
    Yokohama, Kanagawa, Japan
  • National Hospital Organization Kumamoto Saishyunsou Hospital
    Koushi-shi, Kumamoto, Japan
  • Saka General Hospital/Respiratory
    Shiogama, Miyagi, Japan
  • National Hospital Organization Matsumoto Medical Center Chushin Matsumoto Hospital
    Matsumoto, Nagano, Japan
  • Japanese Red Cross Nagasaki Genbaku Isahaya Hospital
    Isahaya, Nagasaki, Japan
  • Nagasaki University School of Medicine
    Nagasaki-city, Nagasaki, Japan
  • National Hospital Organization Minami-Okayama Medical Center
    Tsukubo-gun, Okayama, Japan
  • National Hospital Organization Ureshino Medical Center
    Ureshino-shi, Saga, Japan
  • Sekishinkai Sayama Hospital
    Sayama, Saitama, Japan
  • National Hospital Organization Tenryu National Hospital
    Hamamatsu, Shizuoka, Japan
  • Fukuoka Sanno Hospital
    Fukuoka, Japan
  • National Hospital Organization Kochi National Hospital
    Kochi, Japan
  • Saiseikai Kumamoto Hospital
    Kumamoto, Japan
09

References and documents

Publications

  • Kohno S, Tateda K, Mikamo H, Kadota J, Niki Y, Itamura R. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study. J Infect Chemother. 2015 Mar;21(3):182-8. doi: 10.1016/j.jiac.2014.11.006. Epub 2014 Nov 20. PubMed 25533886 ↗
  • Soto E, Shoji S, Muto C, Tomono Y, Marshall S. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. Br J Clin Pharmacol. 2014 Mar;77(3):509-21. doi: 10.1111/bcp.12232. PubMed 24102758 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2010
First posted
Aug 26, 2010
Start
Oct 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
May 18, 2012
Last update
Jul 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01189487
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 26, 2010
Start date
Oct 2010
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
May 18, 2012
Last update
Jul 13, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ampicillin · Sulbactam

Start the discussion